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ABSTRACT 
The present study deals with the formulation and evaluation of transdermalpatches of meloxicam towards enhance its permeation through the 
skin and maintain the plasma levelconcentration. Transdermal patches were prepared by using polymers like Chitosan, HPMC 15cps and EC 
20cpsat various concentrations by solvent casting technique employing dibutyl phthalate as plasticizer and isopropylmyristate as permeation 
enhancer. The transdermal patches were evaluated for their physico-chemical properties and in-vitro drug release. The transdermal patches 
were found to be transparent and smooth in texture. Amongthe formulations studied, at the end of 12th hour, the minimum and maximum in-
vitro drug release was observedfor the formulations F12 and F4i.e. 80.012 ± 2.012 % and 98.365±3.012%. The mechanism of drugrelease was 
found to be Non-Fickian diffusion controlled. FT-IR studies revealed theintegrity of the drug in theformulations. 
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INTRODUCTION 
Transdermal drug delivery system has been in existence for 
a long time. In the past, the most commonly applied systems 
were topically applied creams and ointments for 
dermatological disorders the occurrence of systemic side-
effects with some of these formulations is indicative of 
absorption through the skin1. A number of drugs have been 
applied to the skin for systemic treatment. In a broad sense, 
the term transdermal delivery system includes all topically 
administered drug formulations intended to deliver the 
active ingredient into the general circulation2.  
Transdermal therapeutic systems have been designed to 
provide controlled continuous delivery of drugs via the skin 
to the systemic circulation3-4.Moreover, it over comes 
various side effects like painful delivery of the drugs and the 
first pass metabolism of the drug occurred by other means of 
drug delivery systems5.     
Meloxicam and other NSAIDs the mechanism of release was 
diffusion mediated. The developed transdermal patches 
increase the efficacy of meloxicam for the therapy of arthritis 
and other painful muscular conditions6-8. Conventional 
systems of medication which require multi dose therapy 
have numerous problems and most recently, there is an 
increasing recognition that the skin can serve as the 
portprovide continuous transdermal drug infusion into the 
systemic circulation9-12. Transdermal therapeutic systems 
are defined as self-contained, discrete dosage forms when 
applied to the intact skin deliver the drug through the skin at 
controlled rate to the systemic circulation15-19. So, in present 
study formulated, evaluated and in-vitrodrug release studies 
of meloxicam. 
MATERIALAND METHODS 
Meloxicam hydrochloride was received as a gift samples 
from Cadila Pharmaceutical, Ahmadabad and polymers are 
obtained from. Other chemicals used in the study were of 
analytical grade. Double-distilled water was used throughout 
the study. 
Preparation of Transdermal Patches 
The transdermal patches of Meloxicam were prepared using 
combination of three polymers i.e. (Chitosan, HPMC, EC) 
(Table 1) in a suitable solvent system by solvent casting 
technique.  Calculated amount of meloxicam was dissolved in 
methanol and was dispersed in polymeric solution. Dibutyl 
phthalate is used as plasticizer (30% weight of polymer) and 
Isopropyl myristate served as permeation enhancer (5% 
weight of polymer) were added and stirred to form uniform 
mixture. The resultant mixture was poured into petridish 
having glass bangle (diameter 4.5 cm) lined with aluminum 
foil as a backing membrane.  The prepared patches were 
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allowed to dry at room temperature for 24 hrs. For complete 
drying, the moulds were kept in a hot air oven maintained at 
45 ± 1ºC for another 4 hours. After complete drying, the 
patches were removed and stored in desiccator until used. 
The patches were smooth, flexible and could be cut to any 
desired size and shape20-26. 
Evaluation of transdermal patches 
The transdermal patches were evaluated for the following 
parameters. 
Physical appearance 
All the prepared patches were visually inspected for color, 
clarity, flexibility and smoothness. 
Thickness uniformity  
The thickness of the formulated film was measured at 3 
different points using a mitutoya thickness gage 7301 made 
in Japan thickness of three reading was calculated. Average 
thickness was determined. 
Folding endurance  
The folding endurance was determined to determine 
flexibility of film.The flexibility of the film is needed to 
handle the film easily and for comfortable, secured 
application of film on the wound. It was determined by 
repeatedly folding one film at same place till it breaks or 
folded up to 300 times manually. The number of times of film 
could be folded at the same place without breaking give the 
value of folding endurance. 
Water absorption capacity  
It is of utmost importance, if they are used for 
biologicalapplications and wound healing. It is used to 
measure the capacity of film to absorb wound exudates. The 
initial weight of 1inch of dry film was noted. Then this film 
was placed in 15ml. of distilled water taken in Petri plate. 
The weight of the film was noted periodically at first hour, 
second hour, third hour and 24th hour. Every time after 
noting the weight, the film was placed in fresh water. Water 
absorption capacity of the film was calculated using a 
formula: 
% moisture absorption =   Final weight – Initial weight     X 100 
                                                            Initial weight 
 
 
Percentage moisture loss 
The films were weighed accurately and kept in a desiccators 
containing anhydrous calcium chloride. After 3 days, the 
films weretaken out and weighed. The moisture losswas 
calculated using the formula: 
     % moisture loss = Initial weight – Final weight  X100 
                                                Initial weight 
 
Water vapor transmission rate  
Glass vials of 5 ml capacity were washedthoroughly and 
dried to a constant weight in anoven. About 1 g of fused 
calcium chloride wastaken in the vials and the polymer films 
of2.25 cm2 were fixed over the brim with thehelp of an 
adhesive tape. Then the vialswere weighed and stored in a 
humiditychamber of 80-90 % RH condition for aperiod of 24 
h. The vials were removedand weighed at 24 h time intervals 
tonote down the weight gain.  
Transmission rate = Final weight – Initial weight     X 100 
                                                               Time x Area 
 
Tensile strength 
Tensile strength of the film was determinedwith Universal 
strength testing machine(JUSTY, Tensile Testing Machine, 
JTM 50 digital). Thesensitivity of the machine was 1 g. 
Itconsisted of two load cell grips. The lowerone was fixed 
and upper one was movable.The test film of size (10 × 10 
mm2) wasfixed between these cell grips and forcewas 
gradually applied till the film broke. The tensile strength of 
the film wastaken directly from the dial reading in kg.Tensile 
strength is expressed as follows: 
Tensile Strength = Tensile load at break 
                                                          Cross section area 
 
Drug content 
An accurately cut patch of 1cm2 area was taken and added to 
a beaker containing 1 ml phosphate buffer solution of pH 7.4 
The beaker was kept 24 hours with occasion shaking. The 
sample was analyzed drug content using UV 
spectrophotometer 248nm.This study was performed for 3 
times for a single patch. 
 
Table 1: Composition of Meloxicam Transdermal Patches 
Formulation 
Code 
Polymers Plasticizer 
(30 % w/v) (DBT) 
Permeation Enhancer 
(30% w/v)  
IPM Chitosan HPMC EC 
F1 5 - - 30 5 
F2 - 5 - 30 5 
F3 2 3 - 30 5 
F4 3 2 - 30 5 
F5 3.5 1 0.5 30 5 
F6 3 1.5 0.5 30 5 
F7 2.5 1.5 1 30 5 
F8 2.5 2.5 0 30 5 
F9 3 1 1 30 5 
F10 2 2 1 30 5 
F11 2.5 2.5 0 30 5 
F12 1.5 3.5 0 30 5 
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In vitro drug release studies 
The in vitro evaluation was carried out in the modified Franz 
diffusion cell. This consists of an upper donor compartment 
and the lower receptor compartment, surrounded by water 
jacket for circulation of water to maintain the temperature 
inside at 32 ±10C.The uniformity of solution in the receptor 
phase was maintained by stirring at high speed of 100 rpm 
(approximately) using a tiny magnetic bead the volume of 
receptor compartment was maintained at 60 ml and the 
diffusional surface are of 0.785 cm2. The receptor 
compartment was provided with the sampling port on one 
side, to withdraw sample at the predetermined time 
intervals for estimation of drug content by UV 
spectrophotometer. 
Experimental conditions 
The receptor medium was phosphate buffer solution of pH 
7.4, temperature of the receptor medium was maintained at 
37 ± 20 C throughout the experiment using water jacket. The 
donor compartment was in contact with ambient condition 
of atmosphere. 
RESULT AND DISCUSSION 
In the present study, Meloxicam transdermal patches were 
prepared by solvent casting method. Polymers used for this 
study Chitosan, HPMC, EC employing aluminum foil as the 
backing membrane, Dibutyl phthalate used as plasticizer and 
Isopropyl myristate as permeation enhancer. 
Thickness 
The transdermal patches were transparent, smooth, uniform 
and flexible. Thicknesses of transdermal patches were found 
to be in the range of 0.02266 ± 0.0015 mm to 0.03533 ± 
0.0025 mm (Table 2). The low standard deviation values in 
the fi lm thickness ensure uniformity of the patches prepared 
by solvent casting technique. The weights of formulations 
were found to be in the range of 0.1130 ± 0.0040 gm to 
0.1736 ± 0.0015 gm. This indicated that there is no 
significant weight variation in all formulations and are as 
shown in Table 2. 
Folding endurance 
In order to evaluate the flexibility, the films were subjected 
to folding endurance studies. The values in the range of 138 
to 176 were observed in all batches. This revealed that the 
preparedfilms were having capability to withstand the 
mechanical pressure along with good flexibility.The 
formulation F6 was found to have lowest folding endurance, 
whereas formulation F4 was found to have highest folding 
endurance. The folding endurance results were shown in 
Table 2. 
Percentage moisture uptake and loss 
Among the formulations, F1 showed maximum moisture 
uptake i.e. 3.4533 ± 0.2318 % and F4 showed minimum 
moisture uptake i.e. 1.3433 ± 0.1457%. The percentage 
moisture uptake results are as shown in Table 2. Among the 
formulations, F10 showed maximum moisture loss i.e. 
4.3300 ± 0.0360 % and F1 showed minimum moisture loss 
i.e. 1.5150 ± 0.2700%. The percentage moisture loss results 
are asshown in Table 2. 
Tensile strength 
The tensile strength was determined by using tensile 
strength tester (Test techno consultant, Vadodara)having the 
capacity of 10 kg. The results are as shown in Table 2. It was 
found that the formulation F4 and F1 shown maximum 
(0.6130 ± 0.0010 kg/cm2) and minimum (0.3250 ± 0.0036 
kg/cm2) tensile strength respectively among all the 
formulations. 
Bursting strength 
The bursting strength was determined by using bursting 
strength tester (Test Techno Consultant, Vadodara)having 
the capacity of 10 kg. From results are as shown in Table 2, it 
is found that the formulation F4 andF8 shown maximum (2.9 
kg/cm2) and minimum (2.2 kg/cm2) bursting strength 
respectively among allthe formulations.  
Drug content uniformity 
The drug content uniformity of all the formulations was 
determined. The results of the drug content inall the 
formulations were found to be in the range of 96.5833 ± 
1.5593 % to 98.4366 ± 0.9281 % and are asshown in Table 2.  
In-vitro drug release 
The results of the Table 3 indicated the cumulative 
percentage drug release of various formulations. 
Thecumulative percentage of drug released in 12 h was 
found to be minimum and maximum for the formulationsF4 
and F10 i.e. 81.023 ± 3.013 % and 98.564 ±3.005%. The in-
vitro release data obtained from different formulations of 
meloxicam was plotted for cumulative percent drug release 
versus time. First order plots are plotted by taking log 
cumulative percent drug remaining versus time. (Figure 1) 
To ascertain the drug release mechanism, the formulations 
were plotted for Higuchi diffusion plots (Figure 2) by taking 
cumulative percent drug release versus square root of time. 
The plots were found to be fairly linearand the regression 
coefficient values were nearer to 1 in all the cases. So it 
confirmed that the drug releasemechanismwas diffusion 
mechanism. The formulations were also treated to Peppa’s 
plot by taking log percent release versus log time (Figure 3). 
The plots are found to be fairly linear and the regression 
values are nearer to 1. The values of slope of peppa’s suggest 
that thedrug was released by Non-Fickian diffusion control 
(Anomalous diffusion) without any swelling. 
CONCLUSION 
The patches of Meloxicam prepared using the polymers 
HPMC 15cps, Chitosan and EC were of smooth surface, good 
appearance, uniform thickness and weight variation with 
minimum standard deviation. The ratio of hydrophilic and 
hydrophobic polymeric fi lm formers affected the mechanical 
properties, percentage moisture uptake and rate of drug 
release. With increasing levels of EC in the formulations the 
release rates were lowered. It can be concluded that 
Meloxicam can be delivered by transdermal route in a 
controlled manner into the systemic circulation to maintain 
therapeutic drug levels for prolonged periods. 
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Table 2: Physical Characterization of Meloxicam Transdermal Patches 
*Average of three determination 
Table 3(a): In-vitro Drug Release Studies 
Time Cumulative Percent Released 
F1 F2 F3 F4 F5 F6 
0 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 
1 4.535±1.042 4.953±1.025 7.025±1.008 8.025±1.025 7.058±3.256 6.456±3.965 
2 11.485±2.365 10.258±1.358 11.852±2.058 18.540±2.004 11.442±2.023 15.665±3.258 
3 19.575±1.358 18.258±1.023 17.458±2.365 24.557±2.014 32.225±3.025 24.369±2.122 
4 27.578±1.025 22.145±2.032 24.258±2.352 33.254±1.250 25.189±2.258 21.258±1.852 
5 32.320±2.025 25.014±1.470 33.591±3.025 23.65±3.034 36.021±2.785 22.568±2.596 
6 42.023±1.235 36.256±2.365 43.258±3.221 48.369±2.325 50.258±2.358 36.223±0.230 
7 51.236±2.369 46.325±2.322 54.203±3.025 55.025±3.780 59.365±3.025 60.254±3.258 
8 59.365±3.252 55.362±2.014 56.236±3.666 58.885±2.258 59.263±2.258 56.254±2.014 
9 66.258±2.365 63.201±3.025 72.025±2.367 76.365±3.247 68.325±2.015 63.021±2.014 
10 74.365±3.202 72.365±2.012 70.367±1.025 73.036±2.025 74.012±2.012 72.032±3.012 
11 75.125±3.012 76.212±2.201 77.012±3.036 75.012±3.312 74.014±2.012 76.012±3.063 
12 86.015±1.005 83.012±2.012 95.850±1.025 98.365±3.012 90.254±1.025 96.025±1.022 
 
Table 3(b): In-vitro Drug Release Studies 
Time Cumulative Percent Released 
F7 F8 F9 F10 F11 F12 
0 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 
1 8.025±1.025 6.456±3.965 7.025±1.008 4.535±1.042 7.058±3.256 4.953±1.025 
2 18.540±2.004 15.665±3.258 11.852±2.058 11.485±2.365 11.442±2.023 10.258±1.358 
3 24.557±2.014 24.369±2.122 17.458±2.365 19.575±1.358 32.225±3.025 18.258±1.023 
4 33.254±1.250 21.258±1.852 24.258±2.352 27.578±1.025 25.189±2.258 22.145±2.032 
5 23.65±3.034 22.568±2.596 33.591±3.025 32.320±2.025 36.021±2.785 25.014±1.470 
6 48.369±2.325 36.223±0.230 43.258±3.221 42.023±1.235 50.258±2.358 36.256±2.365 
7 55.025±3.780 60.254±3.258 54.203±3.025 51.236±2.369 59.365±3.025 46.325±2.322 
8 58.885±2.258 56.254±2.014 56.236±3.666 59.365±3.252 59.263±2.258 55.362±2.014 
9 76.365±3.247 63.021±2.014 72.025±2.367 66.258±2.365 68.325±2.015 63.201±3.025 
10 73.036±2.025 72.032±3.012 70.367±1.025 74.365±3.202 74.012±2.012 72.365±2.012 
11 75.012±3.312 76.012±3.063 77.012±3.036 75.125±3.012 74.014±2.012 76.212±2.201 
12 97.365±3.012 96.025±1.022 95.850±1.025 86.015±1.005 90.254±1.025 80.012±2.012 
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